The abstract is read at the publisher; the summary is JClub's.
Advanced platinum approaches for triple-negative breast cancer are being expanded beyond standard cytotoxicity, leveraging Pt(IV) prodrugs, targeted complexes, and tumor-responsive delivery to address resistance and toxicity.
- Why it matters: Clinical benefit from platinum in TNBC is limited by resistance, treatment-related toxicity, and imperfect patient stratification, despite DNA crosslinking being the main antitumor mechanism.
- What they did: The review synthesizes recent work on Pt(IV) prodrugs, multifunctional agents, subcellularly targeted complexes, and responsive delivery, alongside vulnerabilities such as homologous recombination deficiency, immunogenic cell death, ferroptosis, and DNA damage response dependencies.
- The result: It argues that advanced translational models and biomarker-guided stratification may help convert these vulnerabilities and delivery advances into more precise platinum-based therapeutic strategies for TNBC.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.